Poster abstracts
13
Results: Among respondents with PsO alone 38.9% had seen a
dermatologist in the past year, and 10.7% had never seen a derma-
tologist; 60.9% of those with PsA ± PsO had seen a rheumatologist
in the past year; 14.3% had never seen a rheumatologist. Systemic
treatments had been used by 14.6% of respondents with PsO alone
and 58.5% with PsA ± PsO. Respondents with self-perceived severe
symptoms and patient organization members (POMs) were more
likely than those with non-severe symptoms or non-members, to
have discussed systemic treatments with their physician and to
have used the treatments; however, 35.2% of respondents with
self-perceived severe symptoms had never discussed systemic
treatment with their physician. Asked about long-term health risks
of systemic treatments, 18–44 year-olds and POMs were less likely
to answer “don’t know” than 45–74 year-olds (47.7%–49.1% vs
66.7%–72.9%) or non-members (26.1%–30.7% vs 66.8%–70.4%).
Biologics had been used by 40.7% of POMs vs 6.9% of non-
members, and 21.5% of 18–44 year-olds vs 8.1% of 45–74 year-
olds. Among respondents using oral/injectable methotrexate 30.5%
were dissatisfied, 60.2% citing side-effects as the reason; 22.9%
of biologics users were dissatisfied, 28.9% citing lack of effect
and 28.1% citing side-effects.
Conclusion: In Scandinavia POMs and young patients are more
likely to receive systemic treatment. A high proportion of patients
are dissatisfied with their treatment because of side effects. a normal everyday life (83%), and needing less time for daily
treatment (80%). Based on a clinically meaningful PBI score
≥1, 78% of pts achieved a benefit with APR after 6 mo. Mean
(SD) PBI score was 2.2 (1.3) and increased to 2.5 (1.2) for pts
on continued APR at 6 mo vs 1.6 (1.3) for pts who discontinued
APR. Pts achieved benefit related to skin involvement (60%),
confidence in healing (70%), itch (69%), side effects (60%), be-
ing able to lead a normal everyday life (72%), and needing less
time for daily treatment (65%). Consistent with phase 3 studies,
most frequently reported AEs were diarrhea (19.2%), nausea
(16.4%), and headache (11.5%); 25% of pts reported weight loss
(no change, 71%; gain, 4%).
Conclusions: This interim analysis indicates main pt needs from a
therapy extend beyond skin improvement. Findings indicate APR
may address diverse pt needs.
P024 Dermatologikum Hamburg and SCIderm Research Institute, Hamburg,
Praxis Dr. med. S. Rotterdam, Gelsenkirchen-Feldmark, 3 Priv. Doz. Dr.
med. Korge, Düren, 4 Derma Nord Hautarztpraxen Dr. med. Schwichten-
berg, Bremen, 5 Celgene GmbH, Munich, Germany
FIRST PATIENT-REPORTED INSIGHTS FROM
A MULTINATIONAL, RETROSPECTIVE, CROSS-
SECTIONAL STUDY OF REAL-WORLD EXPERIENCE
OF PSORIASIS PATIENTS TREATED WITH
APREMILAST IN CLINICAL DERMATOLOGY
PRACTICE (APPRECIATE)
Matthias Augustin 1 , Marc Alexander Radtke 1 , Kilian Eyerich 2 ,
Mona Ståhle 3 , Christine Bundy 4 , Myriam Cordey 5 , Volker Kosci-
elny 5 , C. Elise Kleyn 6 , Christopher EM Griffiths 6
Institute for Health Services Research in Dermatology and Nursing,
University Medical Center Hamburg-Eppendorf, Hamburg, 2 Department
of Dermatology and Allergy, Technical University of Munich, Munich,
Germany, 3 Department of Medicine, Karolinska Institute, Solna, Sweden,
4
School of Healthcare Sciences, College of Biomedical and Life Sciences,
Cardiff University, Cardiff, UK, 5 Celgene International, Boudry, Switzer-
land, 6 Dermatology Centre, Salford Royal NHS Foundation Trust, Univer-
sity of Manchester, Manchester Academic Health Science Centre, Man-
chester, UK
1
Introduction: Patient (pt)-centered care is gaining traction in
long-term disease management. We report on a multinational,
retrospective, cross-sectional study in psoriasis pts treated with
apremilast (APR), an oral phosphodiesterase 4 inhibitor, in a real-
world clinical setting.
Objectives: The study aims to identify important pt needs and
therapeutic benefits of APR.
Methods: Consecutive pts with chronic plaque psoriasis treated
according to routine clinical practice who could be contacted
6 ± 1 mo after APR initiation were enrolled. Medical chart review,
standardized pt-reported outcome tools (PBI, TSQM-9), and pt/
physician questionnaires were used. An interim analysis of the first
104 pts from 40 sites in Germany (42), UK (31), and Sweden (31)
was performed using predefined descriptive statistics.
Results: 102 pt questionnaires were analyzed (98%). At 6 ± 1 mo,
74 pts (71%) continued APR; 30 (29%) had discontinued APR
(lack of efficacy [14%], safety/tolerability [11%], other [4%]).
Assessment of pts’ main needs from a therapy (quite/very im-
portant on the PBI) revealed the importance pts attributed to skin
involvement (93% of responders), confidence in healing (92%),
being itch free (85%), fewer side effects (84%), being able to lead
Prior Presentation: EADV 2017
P025
PHYSICIAN- AND PATIENT-REPORTED OUTCOMES
WITH APREMILAST FOR PATIENTS WITH PLAQUE
PSORIASIS DURING ROUTINE DERMATOLOGY CARE
IN GERMANY: A SECOND INTERIM ANALYSIS
Kristian Reich 1 , Stefanie Bomas 2 , Bernhard Korge 3 , Uwe Schwich-
tenberg 4 , Hannah Mentz 5 , Kathrin Groegel 5 , Natalie Núnez Gómez 5
1
2
Introduction: LAPIS-PSO is an ongoing, 52-week, prospective,
multicenter, observational cohort study in real-world dermatology
clinical settings in Germany.
Objectives: To present a 4-month interim analysis of patient (pt)-
reported outcomes and efficacy assessments of apremilast (APR)
among pts (n = 294; full analysis set [FAS], n = 1